Dr. Curigliano Discusses Immunotherapy in Breast Cancer
Giuseppe Curigliano, MD, PhD
Giuseppe Curigliano, MD, PhD, head of the Division of Early Drug Development at European Institute of Oncology, in Milan, Italy, discusses the emergence of immunotherapy in breast cancer.
The combination of checkpoint inhibitors and chemotherapy is showing the most promise, says Curigliano, specifically in certain patients with triple-negative breast cancer (TNBC). Though this combination is showing results in some patients, Curigliano adds that it is not for all patients with breast cancer, or even all patients with TNBC.
Focus needs to be put on patient selection to optimize immunotherapy as a treatment in this disease. This should start with individual assessment of tumor-infiltrating lymphocytes in patients with TNBC, according to Curigliano.